Newell Rubbermaid announces new executive appointments as part of restructuring plan
ATLANTA – In addition to an extensive structural makeover, dubbed the "Growth Game Plan", Newell Rubbermaid president and CEO Mike Polk announced a new leadership team that includes outside appointments to several executive positions.
Among these new appointments is Joe Cavaliere, former SVP customer development for Unilever, who will serve as chief customer officer at Newell Rubbermaid. In this new role, Cavaliere will help globalize the company’s customer development organization, and expand customer partnerships and collaborations around the world. Among his 29 years of experience, Cavaliere helped catapult Unilever to a top 5 ranking in the consumer good industry during his nine-year career at the company.
Richard Davies — also formerly of Unilever, as head of global insights — will join Newell Rubbermaid as chief marketing & insights officer. Davies brings more than 30 years of marketing, insights and brand strategy experience to the new position.
Mark Tarchetti, former head of global corporate strategy at Unilever, will join Newell Rubbermaid in January as chief development officer — leading the new development organization. Tarchetti founded international consulting firm Tarchetti & Co and has been supporting the development of Newell Rubbermaid’s new business strategy over the last year.
"The structural and leadership changes we are announcing today are bold steps that are critical to unlocking our full growth potential," Polk said.
Survey: Retailers plan to spend more on e-commerce this year
DURHAM, N.C. — More than two-fifths of retailers plan to increase spending on online marketing this year, and nearly half have invested in new mobile apps, according to a new survey.
The survey, titled "Loading the Sleigh: Marketers’ Plans & Expectations for the Holiday Season," conducted by Retail Systems Research on behalf of Bronto Software over the summer, included 179 respondents, mostly with annual sales of between $51 million and $999 million. Bronto makes software for retailers and other commerce-focused companies.
Sixty-eight percent of respondents said they expect sales to increase from last year, with more than a quarter saying sales will increase by more than 50%. At the same time, 21% said they would "significantly" increase online marketing budgets compared with 2011, while 22% plan to slightly increase them.
"Retailers clearly recognize the need to market online during the holidays, when they are under the most pressure to capture consumer wallet share," Bronto CEO Joe Colopy said. "This study shows that these marketers have made important investments over the year, so they are poised to accomplish their goals. And while mail is a more established channel and has inherent technologic advantages for communicating with consumers, marketers are getting ready to use mobile and social to break out of the pack."
Retailers have made several investments in e-commerce marketing. Forty-nine percent have invested in mobile applications, while 46% have invested in new e-commerce platforms. Fifty percent have found new email service providers, while 43% have invested in mobile website optimization.
But as Colopy suggested, most are budgeting for email marketing, with 87% saying they would spend on that this year and more than half saying they expect the overall volume of emails they send to increase over 2011.
As many as one-third plan to wait until after Black Friday weekend to begin their first promotions, and all are planning to offer free shipping offers.
Chemotherapy drug shows “significant” improvement in melanoma patients in late-stage trial
BOUDRY, Switzerland — A Swiss subsidiary of drug maker Celgene Corp. said its chemotherapy drug produced "significant" improvement in progression-free survival in patients with a deadly skin cancer that had spread elsewhere in the body.
Celgene International Sarl announced the publication of abstracts from its phase-3 trial of Abraxane in melanoma patients in the journal of the Society for Melanoma Research, with plans to present the findings at an upcoming meeting of the organization. Abraxane is a formulation of the drug paclitaxel bound in the human protein albumin and free of solvents already approved for treating several other cancers.
"Metastatic melanoma presents significant treatment challenges due in part to limited therapies, low survival rates at diagnosis and no advances in chemotherapy in 37 years," University of Arizona professor of medicine and lead study investigator Evan Hersh said. "Despite advances with targeted treatment and immunotherapies, there is still a need for new agents, including chemotherapy treatments, for patients with metastatic melanoma."
The trial included patients with metastatic melanoma who had not received chemotherapy before, comparing them to patients receiving dacarbazine chemotherapy. Results of the trial indicate that Abraxane was more effective, Celgene said.